Literature DB >> 25188366

Risks for multidrug-resistant pathogens in the ICU.

Ignacio Martín-Loeches1, Emili Diaz, Jordi Vallés.   

Abstract

PURPOSE OF REVIEW: The impact of multidrug-resistant organisms (MDROs) is rising and often underestimated. The epidemiology of MDROs is extremely complex and multifactorial. There is increasing antibiotic resistance, mainly related to antibiotic pressure and patients' characteristics. RECENT
FINDINGS: Emphasis on MDRO epidemiology is needed to better understand current strategies of prevention and management. Among them, antibiotic stewardship has been one of the most successful strategies. It is important to note that there is a controversial issue when considering community and healthcare-related infections. In addition, different strategies have been determined to find the impact and optimal use of recently launched antibiotics for MDRO treatment.
SUMMARY: Infections with MDROs can prolong hospital stay, promote antibiotic use and prolong duration of mechanical ventilation. Some points should be further explored in clinical research such as the heterogeneity of healthcare-associated pneumonia and the need of new drug development. Resistance to non fermentative Gram-negative bacilli, rising minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus and spread of MDROs in patients without known risk factors suggest a review of guideline validation, taking into account ecology and severity of patient illness to provide timely and appropriate empiric therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25188366     DOI: 10.1097/MCC.0000000000000124

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  21 in total

1.  The Likelihood of Developing a Carbapenem-Resistant Enterobacteriaceae Infection during a Hospital Stay.

Authors:  Pranita D Tamma; Abida Kazmi; Yehudit Bergman; Katherine E Goodman; Ernest Ekunseitan; Joe Amoah; Patricia J Simner
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Duration of antibiotic therapy in the intensive care unit.

Authors:  Gabor Zilahi; Mary Aisling McMahon; Pedro Povoa; Ignacio Martin-Loeches
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

3.  Impact of de-escalation on ICU patients' prognosis.

Authors:  Jan J De Waele; Matteo Bassetti; Ignacio Martin-Loeches
Journal:  Intensive Care Med       Date:  2014-09-13       Impact factor: 17.440

4.  Utilisation of critical care services for surgical patients in a model three hospital.

Authors:  Amy Lee Fowler; Orla Cullivan; Shomik Sibartie; Aidan O'Shea; Ronan Waldron; Iqbal Khan; Waqar Khan; Kevin M Barry
Journal:  Ir J Med Sci       Date:  2019-02-09       Impact factor: 1.568

5.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.

Authors:  Jan J De Waele; Murat Akova; Massimo Antonelli; Rafael Canton; Jean Carlet; Daniel De Backer; George Dimopoulos; José Garnacho-Montero; Jozef Kesecioglu; Jeffrey Lipman; Mervyn Mer; José-Artur Paiva; Mario Poljak; Jason A Roberts; Jesus Rodriguez Bano; Jean-François Timsit; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2017-12-29       Impact factor: 17.440

7.  ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.

Authors:  Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2019-03-25       Impact factor: 17.440

8.  Antimicrobial Susceptibility among Pathogens Isolated in Early- versus Late-Onset Ventilator-Associated Pneumonia.

Authors:  Hend Ben Lakhal; Aymen M'Rad; Thierry Naas; Nozha Brahmi
Journal:  Infect Dis Rep       Date:  2021-04-27

9.  No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

Review 10.  STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship.

Authors:  Evelina Tacconelli; Maria A Cataldo; M Paul; L Leibovici; Jan Kluytmans; Wiebke Schröder; Federico Foschi; Giulia De Angelis; Chiara De Waure; Chiara Cadeddu; Nico T Mutters; Petra Gastmeier; Barry Cookson
Journal:  BMJ Open       Date:  2016-02-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.